Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Senators call for FDA nanotech program

Executive Summary

Bill introduced by Sens. Mark Pryor (D-Ark.) and Benjamin L. Cardin (D-Md.) would establish an FDA program "to assess the health and safety implications of nanotechnology in everyday products and develop best practices for companies that employ nanotechnology." In a Jan. 21 release, Pryor states: "As these products are developed and used, we must understand any potential risks to human health, safety or the environment." He maintains that FDA's involvement "will help ensure public safety and confidence in the marketplace" and support firms using nano-sized materials. Legislation would authorize $25 million annually from 2011 through 2015 to fund the program. FDA already has facilities in place to conduct studies required under the bill, including the National Center for Toxicological Research in Arkansas and its consolidated headquarters in Maryland, Pryor notes. In August 2009, the Project on Emerging Nanotechnologies had netted more than 600 health and fitness products - including cosmetics and personal-care items - in its database of nanotechnology-containing consumer goods marketed worldwide (1"The Rose Sheet" Sept. 7, 2009)
Advertisement

Related Content

Health Products Lead Rapidly Expanding Nanotechnology Product List
Health Products Lead Rapidly Expanding Nanotechnology Product List
Advertisement
UsernamePublicRestriction

Register

RS016691

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel